March 8, 2011 -
PRLog -- The global Methicillin-
resistant Staphylococcus aureus (MRSA) market was valued at $900m in 2010 and is forecast to grow at a Compound Annual Growth Rate (CAGR) of 4.8% for the next seven years to reach $1,249m by 2017. The growth will primarily be driven by an increase in the average number of days spent in the hospitals due to inappropriate initial antibiotic treatment and steady increases in elderly and immuno-suppressed populations. At present, the market has six approved therapies, out of which Vancomycin and Synercid (quinupristin+
dalfopristin)
are generic and the other four are branded drugs. Currently, the market is dominated by drugs like Vancomycin, Zyvox (linezolid) and Cubicin (daptomycin)
. As the disease is curable when identified in time, the unmet need seems to be low. Although the existing drugs such as Vancomycin, Zyvox, Cubicin, Tygacil (tygecycline)
, Vibativ (televancin)
and Synercid are capable of curing the disease, there are still unmet needs which can be tapped with those emerging agents which have better safety profiles.
Pfizer, Theravance Inc., and Cubist Pharmaceuticals remain the leading competitors in the global MRSA therapeutics market. The competitive landscape is strong, with six approved therapies. The market remains highly consolidated. These players captured the market in the past few years and are expected to be the market leaders for next three to four years with products like Zyvox, Cubicin and Vibativ until new players emerge, like Takeda/Forest with ceftaroline, Basilea with ceftobiprole, Trius with Torezolid (TR-701) and Paratek with PTK0796 enter into the market which will intensify the competition in the future.
For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....In the pipeline, 38 products were in different developmental stages as of December 2010. Takeda/Forest’
s Teflaro (ceftaroline)
, Basilea’s Ceftobiprole and Trius’s Torezolid phosphate are the key products currently in the pipeline. The emergence of promising agents such as Oritavancin (LY333328) and TD-1792 with novel mechanisms of action would intensify the competition.
GlobalData, the industry analysis specialist, has released its new report, “Methicillin-
Resistant Staphylococcus Aureus (MRSA) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global MRSA market. The report identifies the key trends shaping and driving the global MRSA market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global MRSA sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Meth...Visit our report store:
http://www.globaldata.comFor more details contact:
pressreleases@
globaldata.com
North America: +1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782
# # #
GlobalData is a global market intelligence services company providing information research and analysis products and services.
Account Phone Number